Følg Karo Pharma

Pressemeldinger

SIMEN NYBERG-HANSEN - NY ADMINISTRERENDE DIREKTØR I WEIFA

Pressemeldinger   •   nov 27, 2017 12:00 CET

Simen Nyberg-Hansen ansettes som ny administrerende direktør i Weifa.

Oppfriskende nyhet fra Weifa: Nazamér Mentol
Weifa ASA to launch Ibux® 200 mg soft capsules to strengthen its pain relief portfolio.

Weifa ASA to launch Ibux® 200 mg soft capsules to strengthen its pain relief portfolio.

Pressemeldinger   •   okt 11, 2016 16:00 CEST

Weifa ASA is pleased to announce the launch of Ibux® 200 mg soft capsules, a line extension to the already well established Ibux® range.

Weifa ASA to launch Solvivo® - a new OTC product for sore throat in Norway.

Weifa ASA to launch Solvivo® - a new OTC product for sore throat in Norway.

Pressemeldinger   •   sep 14, 2016 13:35 CEST

Weifa ASA is pleased to announce the launch of Solvivo® lozenges. With Solvivo® Weifa enters the OTC throat segment, which has had a value growth of 64% last twelve months, and represents a value of MNOK 11 last twelve months (pharmacy purchasing price). This is the fastest growing segment within the Cough & Cold category.

Weifa ASA to launch  a new medicinal product for  insomnia in Norway

Weifa ASA to launch a new medicinal product for insomnia in Norway

Pressemeldinger   •   aug 10, 2016 14:58 CEST

Weifa ASA is pleased to announce the launch of Zonat® tablets, which is indicated for short-term symptomatic treatment of occasional insomnia in adults over 18 years old. Zonat® contains the antihistamine doxylamine, which is well established as a non-prescription (OTC) product for occasional insomnia in several European countries. In Norway Zonat® will require medical prescription.

Distribution agreement in Finland for unique pain products

Distribution agreement in Finland for unique pain products

Pressemeldinger   •   jun 06, 2016 13:30 CEST

Weifa has signed a 5-year distribution agreement with the Fysioline Group (Finland). The agreement covers several of Weifa’s most recently launched products within the pain category, and can be extended to include additional products.